SEC Company Response from TENAX THERAPEUTICS, INC. (TENX) (CIK 0000034956) (TENX) — Sep 8, 2004

TENAX THERAPEUTICS, INC. (TENX) (CIK 0000034956)
Date: Sept. 8, 2004 · CIK: 0000034956 · Accession: 0001020488-04-000050

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-118759

Date

September 8, 2004

Author

Not clearly detected

Form

CORRESP

Company

TENAX THERAPEUTICS, INC. (TENX) (CIK 0000034956)

Letter

Via EDGAR and Fax to (202) 942-9533 SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance 450 Fifth Street, N.W. Washington D.C. 20549-0304 Attn: Suzanne Hayes, Mail Stop 0309 Re: Registration Statement on Form S-2 SEC File No. 333-118759

Dear Ms. Hayes:

Pursuant to Rule 461 of Regulation C, Synthetic Blood International, Inc. (“Company”), hereby requests acceleration of the effective date of the above-referenced registration statement on Form S-2 to Friday, September 10, 2004 at 12:00 Noon. We confirm that a copy of our annual report on Form 10-K for the year ended April 30, 2004 will be sent with each copy of the prospectus we deliver, as stated on the cover page of the prospectus.

No broker-dealer is listed in the registration statement as participating as an underwriter, so no filing was made with the National Association of Securities Dealers, Inc. in the absence of a requirement to do so. With respect to dissemination of information contemplated by Rules 460 and 461, offers will be made directly by selling security holders by delivering a copy of the final prospectus to prospective purchasers. This will confirm that the Company is aware of its obligations under the Securities Act of 1933 and the Securities and Exchange Act of 1934.

We hereby acknowledge that:

Should the Securities and Exchange Commission (“Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance Attn: Suzanne Hayes, Mail Stop 0309 September 8, Page 2

The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

The Company may not assert this action as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Sincerely,
Synthetic Blood International, Inc.

Show Raw Text

CORRESP
1
filename1.htm

     Synthetic Blood
International, Inc.

3189 Airway Avenue, Bldg.
C

Costa Mesa, CA 92626

714-427-6363

Fax 714-427-6361

September 8, 2004

Via EDGAR and Fax to
(202) 942-9533

SECURITIES AND EXCHANGE COMMISSION

Division of Corporation Finance
450 Fifth Street, N.W.
Washington D.C. 20549-0304

Attn:
                Suzanne
Hayes, Mail Stop 0309

     Re:
     Registration
Statement on Form S-2

     SEC File No. 333-118759

Dear Ms. Hayes:

        Pursuant
to Rule 461 of Regulation C, Synthetic Blood International, Inc. (“Company”),
hereby requests acceleration of the effective date of the above-referenced registration
statement on Form S-2 to Friday, September 10, 2004 at 12:00 Noon. We confirm that a copy
of our annual report on Form 10-K for the year ended April 30, 2004 will be sent with
each copy of the prospectus we deliver, as stated on the cover page of the prospectus.

        No
broker-dealer is listed in the registration statement as participating as an underwriter,
so no filing was made with the National Association of Securities Dealers, Inc. in the
absence of a requirement to do so. With respect to dissemination of information
contemplated by Rules 460 and 461, offers will be made directly by selling security
holders by delivering a copy of the final prospectus to prospective purchasers. This will
confirm that the Company is aware of its obligations under the Securities Act of 1933 and
the Securities and Exchange Act of 1934.

        We
hereby acknowledge that:

Should the
Securities and Exchange Commission (“Commission”) or the staff, acting pursuant
to delegated authority, declare the filing effective, it does not foreclose the
Commission from taking any action with respect to the filing;

SECURITIES AND EXCHANGE
COMMISSION
Division of Corporation Finance
Attn: Suzanne Hayes, Mail Stop 0309
September 8,
2004
Page 2

The action of the Commission or the staff, acting pursuant to delegated authority, in
declaring the filing effective, does not relieve the Company from its full responsibility
for the adequacy and accuracy of the disclosure in the filing; and

The Company may not assert this action as defense in any proceeding initiated by the
Commission or any person under the federal securities laws of the United States.

     Sincerely,

     Synthetic Blood International, Inc.

     /s/ David Johnson, Chief Financial Officer

SecProbe.io